混合ポリオワクチン市場：ワクチンタイプ別、投与経路別、技術別、新興国開拓段階別、エンドユーザー別-2025～2030年の世界予測

混合ポリオワクチン市場は、2024年には28億6,000万米ドルとなり、2025年には29億7,000万米ドル、CAGR 3.98%で成長し、2030年には36億2,000万米ドルに達すると予測されています。

世界の医療制度が予防接種戦略を見直すにつれて、混合ポリオワクチン市場は変貌しつつあります。近年、複数のワクチン製剤を1回の接種量に統合することで、予防接種率を向上させるだけでなく、公衆衛生のロジスティクスを合理化する絶好の機会がもたらされています。この技術革新は、特にヘルスケア資源が手薄な地域において、効率的かつ効果的な予防接種という重要なニーズに応えるものです。混合ワクチンのコンセプトの進化は、数十年にわたる臨床研究、科学的協力、進歩的な公衆衛生政策に根ざしています。ポリオ撲滅に再び焦点が当てられる中、政策立案者、研究者、産業界のリーダーたちは、包括的な予防を提供する一方で、複数回の注射投与に伴うコストや複雑さを削減するワクチン投与方法の改良を模索してきました。

さらに、単一の製剤でさまざまな病原体をカバーできるワクチンへの需要が高まっていることは、利害関係者が革新的なヘルスケアソリューションを受け入れる用意があることを裏付けています。このようなワクチンの統合は、緊急の予防接種目標を満たすだけでなく、予防ヘルスケア・インフラの戦略的重要性を強化するものでもあります。疾病パターンが進化し、新たな健康リスクが出現するにつれて、混合ワクチンの役割はさらに重要になります。このようなダイナミックな環境において、市場は精力的な調査、急速な技術強化、規制当局の支援を受け、ワクチンの供給と公衆衛生の成果における画期的な進歩への道を切り開いています。

混合ポリオワクチン市場の変革

最近のワクチン技術の進歩と世界の公衆衛生の優先順位の変化により、混合ポリオワクチンの状況は大きく変化しています。革新的な研究開発により、複数の成分をより強力な製剤に統合したワクチンが開発され、医療従事者が直面する物流の負担が大幅に軽減されました。このような開発の背景には、接種回数が少なく、変異株に対する予防効果が持続する、費用対効果の高い予防接種プログラムに対する需要の高まりがあります。

同時に、デジタルヘルスとリアルタイムデータ解析の新たな動向は、意思決定者に実用的な洞察力を与えています。これらの技術は臨床試験や規制当局の審査を合理化し、混合ワクチンの迅速な市場参入を可能にします。さらに、国民の意識の向上と政府主導の健康キャンペーンがワクチン摂取を増加させ、市場の勢いをさらに加速させています。このようなダイナミックな環境は、バイオテクノロジー企業、研究機関、政府機関の戦略的パートナーシップによって特徴付けられ、既存および将来の保健上の課題に対処するために調和しています。

市場の進化は、サプライチェーンの混乱や、統合ヘルスケアソリューションに傾倒する消費者行動の変化といった課題への機敏な対応によって特徴付けられます。従来のワクチン供給方法では現代の健康危機への対応がますます不十分になっているように見える中、混合ワクチン戦略は有望な選択肢を提供するものです。ワクチン製剤の絶え間ない改良と強固な市販後調査により、ワクチン接種プログラムに対する国民の信頼は揺るぎないものとなっています。サマリーをまとめると、このような変革的なシフトは、科学の進歩と実用的な保健ソリューションの融合という新時代を浮き彫りにし、世界の公衆衛生の大幅な改善を約束するものです。

混合ポリオワクチン市場の主なセグメンテーション洞察

混合ポリオワクチン市場を詳細に調査すると、その成長の軌跡と戦略的方向性を理解する上で重要な、明確なセグメンテーションの洞察が見えてくる。同市場は、2価ワクチン、1価ワクチン、3価ワクチンなどの製剤を含むワクチンタイプに基づいて分析されています。それぞれの製剤には独自の利点と課題があるため、臨床応用や規制遵守のために独自のアプローチが必要となります。

さらに、投与経路は市場の差別化において重要な役割を担っており、注射剤から経口剤まで、多様な疫学的環境や患者層に合わせて最適化されています。不活化ポリオワクチン、弱毒生ワクチン、サブユニットワクチンは、それぞれ安全性プロファイルと免疫原性効率に異なる貢献をしており、公衆衛生の多様な要件に対応しています。

開発段階による区分は、ワクチンの研究開発における厳格で長期にわたるプロセスを反映しています。第I相、第II相、第III相、さらには前臨床研究を含む重要な臨床試験は、それぞれの混合ワクチンが安全かつ有効であることを保証するために費やされている強固な努力を示しています。さらに、クリニック、地域保健センター、病院、公衆衛生研究所を含むエンドユーザー部門は、これらのワクチンが実施されているヘルスケア環境の広範さを強調しています。これらの各セグメントは、複合ポリオワクチンの戦略的市場シナリオを形成する複雑さとチャンスをもたらしています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 出生率の上昇と人口増加により、地域全体で小児用ワクチンの需要が高まっている
    • 予防医療への重点が高まり、混合ワクチンの接種が促進される
    • 政府と非政府による支援キャンペーンがワクチンの接種と配布を促進
  • 抑制要因
    • 流通中にワクチンの有効性を維持するためのコールドチェーン物流と輸送の複雑さ
  • 機会
    • 最適な混合ポリオワクチン効果のためのコールドチェーンインフラの改善への投資増加
    • さまざまな気候下でのワクチンの保存と長期保存を改善するための継続的な研究開発
  • 課題
    • 複数の世界市場で承認を得るための大きな規制上のハードル
• 市場セグメンテーション分析
  • ワクチンの種類：2つのポリオウイルス株を標的とし、カバー範囲と費用対効果のバランスを実現する二価ワクチンの必要性が高まっている
  • 開発段階：
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 混合ポリオワクチン市場ワクチンの種類別

• 二価ワクチン
• 一価ワクチン
• 三価ワクチン

第7章 混合ポリオワクチン市場：投与経路別

• 注射剤投与
• 経口投与

第8章 混合ポリオワクチン市場：技術別

• 不活化ポリオウイルスワクチン
• 生弱毒化ワクチン
• サブユニットワクチン

第9章 混合ポリオワクチン市場開発段階別

• フェーズI臨床試験
• フェーズII臨床試験
• フェーズIII臨床試験
• 前臨床試験

第10章 混合ポリオワクチン市場：エンドユーザー別

• クリニック
• コミュニティヘルスセンター
• 病院
• 公衆衛生研究所

第11章 南北アメリカの混合ポリオワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の混合ポリオワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの混合ポリオワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bharat Immunologicals and Biologicals Corporation Limited
• Biological E. Limited
• BioNTech SE
• CSL Limited
• Daiichi Sankyo Company, Limited.
• GlaxoSmithKline PLC
• Haffkine Bio-Pharmaceutical Corporation Ltd
• Incepta Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Limited
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. COMBINED POLIO VACCINE MARKET MULTI-CURRENCY
• FIGURE 2. COMBINED POLIO VACCINE MARKET MULTI-LANGUAGE
• FIGURE 3. COMBINED POLIO VACCINE MARKET RESEARCH PROCESS
• FIGURE 4. COMBINED POLIO VACCINE MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. COMBINED POLIO VACCINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. COMBINED POLIO VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. COMBINED POLIO VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COMBINED POLIO VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY BIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TRIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INACTIVATED POLIOVIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PRE-CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. COMBINED POLIO VACCINE MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 238. COMBINED POLIO VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

The Combined Polio Vaccine Market was valued at USD 2.86 billion in 2024 and is projected to grow to USD 2.97 billion in 2025, with a CAGR of 3.98%, reaching USD 3.62 billion by 2030.

The combined polio vaccine market is transforming as global health systems recalibrate their immunization strategies. In recent years, the integration of multiple vaccine formulations into a single dose has presented a tremendous opportunity to not only enhance immunization coverage but also streamline public health logistics. This innovation addresses the critical need for efficient and effective immunization, particularly in regions where healthcare resources are stretched thin. The evolution of the combined vaccine concept is rooted in decades of clinical research, scientific collaboration, and progressive public health policies. With the renewed focus on eliminating polio, policymakers, researchers, and industry leaders have sought to refine vaccine delivery methods that offer comprehensive protection while cutting down on costs and complexities associated with administering multiple injections.

Furthermore, the rising demand for vaccines that can cover a spectrum of pathogens within a single formulation underscores the readiness of stakeholders to embrace innovative healthcare solutions. This consolidation of vaccines not only meets urgent immunization targets but also reinforces the strategic importance of preventive healthcare infrastructure. As disease patterns evolve and new health risks emerge, the role of combined vaccines becomes even more significant. In this dynamic environment, the market is witnessing a period of vigorous research, rapid technological enhancements, and regulatory support that together pave the way for groundbreaking advancements in vaccine delivery and public health outcomes.

Transformative Shifts in the Vaccine Landscape

Recent advancements in vaccine technology and a shift in global public health priorities have set the stage for transformative changes in the combined polio vaccine landscape. Innovative research has led to the development of vaccines that integrate multiple components into single, more potent formulations, drastically reducing the logistical burdens faced by healthcare providers. Such developments have been fueled by an increasing demand for cost-effective immunization programs that require fewer doses and offer extended protection against mutated strains.

At the same time, emerging trends in digital health and real-time data analytics are empowering decision-makers with actionable insights. These technologies streamline clinical trials and regulatory reviews, enabling faster market entry for combined vaccine formulations. Additionally, enhanced public awareness and government-led health campaigns have increased vaccine uptake, further accelerating market momentum. This dynamic environment is characterized by strategic partnerships between biotech companies, research institutions, and government bodies that work in harmony to address both existing and future health challenges.

Market evolution is marked by an agile response to challenges such as supply chain disruptions and shifts in consumer behavior that lean towards integrated healthcare solutions. As traditional vaccine delivery methods appear increasingly inadequate in addressing modern health crises, the combined vaccine strategy offers a promising alternative. The continual refinement of vaccine formulations coupled with robust post-market surveillance assures that public confidence in vaccination programs remains unwavering. In summary, these transformative shifts highlight a new era of convergence between scientific advancement and practical health solutions, promising significant improvements in public health globally.

Key Segmentation Insights in the Combined Polio Vaccine Market

A closer examination of the combined polio vaccine market reveals distinct segmentation insights that are critical to understanding its growth trajectory and strategic direction. The market is analyzed based on vaccine type, which encompasses formulations such as bivalent, monovalent, and trivalent vaccines. Each formulation presents unique benefits and challenges, necessitating tailored approaches for clinical application and regulatory compliance.

Additionally, the route of administration plays a crucial role in market differentiation, where solutions ranging from injectable administration to oral administration have been optimized to suit diverse epidemiological settings and patient demographics. The incorporation of advanced technologies is another key segment; inactivated poliovirus vaccines, live attenuated vaccines, and subunit vaccines each contribute differently to safety profiles and immunogenicity efficiencies, thus catering to varied public health requirements.

The segmentation based on development stage further reflects the rigorous and often lengthy process involved in vaccine research and development. Critical clinical trials, including phase I, phase II, phase III, and even pre-clinical research, indicate the robust efforts being invested in ensuring that each combined vaccine is both safe and effective. Moreover, the end user segment, which includes clinics, community health centers, hospitals, and public health laboratories, underscores the broad spectrum of healthcare settings where these vaccines are being implemented. Each of these segments contributes a layer of complexity and opportunity that collectively shapes the strategic market narrative for combined polio vaccinations.

Based on Vaccine Type, market is studied across Bivalent Vaccine, Monovalent Vaccine, and Trivalent Vaccine.

Based on Route Of Administration, market is studied across Injectable Administration and Oral Administration.

Based on Technology, market is studied across Inactivated Poliovirus Vaccines, Live Attenuated Vaccines, and Subunit Vaccines.

Based on Development Stage, market is studied across Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, and Pre-Clinical Trials.

Based on End User, market is studied across Clinics, Community Health Centers, Hospitals, and Public Health Laboratories.

Key Regional Insights Across Major Global Markets

Exploring regional dynamics reveals distinctive characteristics in the adoption and application of combined polio vaccines. In the Americas, mature healthcare frameworks and proactive immunization policies have facilitated seamless integration of innovative vaccine solutions into public health programs. Meanwhile, the Europe, Middle East & Africa region presents a varied landscape where robust regulatory environments and varying levels of healthcare infrastructure coexist, driving a need for adaptable vaccine strategies that cater to both high-income and emerging markets.

In the Asia-Pacific region, rapid industrial growth, increasing population densities, and rising health awareness contribute to a dynamic market environment. Here, the demand for efficacious and economically viable immunization solutions is particularly pronounced as nations strive to meet ambitious vaccination targets while managing resource limitations. Collectively, these regional insights reflect not only the diverse market challenges but also the vast opportunities for strategic investment and public-private collaboration in the ongoing battle to eradicate polio.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Shaping the Vaccination Landscape

An in-depth evaluation of industry players reveals that a diverse range of companies is actively shaping the combined polio vaccine market. Renowned pharmaceutical entities such as Astellas Pharma Inc. and AstraZeneca PLC are making significant strides by investing heavily in research and technology innovations. Companies like Bharat Immunologicals and Biologicals Corporation Limited and Biological E. Limited have carved out vital roles by catering to emerging economies and developing customized vaccine solutions for diverse demographic needs.

Other major industry participants, including BioNTech SE, CSL Limited, and Daiichi Sankyo Company, Limited, play important roles in advancing the scientific underpinnings of vaccine development through robust clinical trials and strategic partnerships. GlaxoSmithKline PLC and Haffkine Bio-Pharmaceutical Corporation Ltd contribute their global expertise in vaccine safety and distribution, which is crucial in maintaining public trust during the immunization process. Further, entities such as Incepta Pharmaceuticals Ltd., Merck & Co., Inc., and Mitsubishi Tanabe Pharma Corporation have demonstrated a commitment to innovation that transcends geographical boundaries, ensuring that the latest technologies reach those in need.

In addition, Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited represent a robust cross-section of the market. Their collective efforts are cementing the foundation for widespread vaccine acceptance and implementation, ultimately contributing to enhanced global immunization outcomes. Together, these companies not only drive market competition but also foster a spirit of innovation that is essential for sustaining long-term health improvements.

The report delves into recent significant developments in the Combined Polio Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bharat Immunologicals and Biologicals Corporation Limited, Biological E. Limited, BioNTech SE, CSL Limited, Daiichi Sankyo Company, Limited., GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to consider a multifaceted strategy to fully capitalize on the dynamic potential within the combined polio vaccine market. To begin with, a continuous investment in research and development activities is crucial in meeting both current and emerging health challenges. Embracing cutting-edge biotechnology and digital health solutions allows companies to achieve faster clinical trial results and enhance vaccine performance. By intensifying efforts in safety protocols and efficacy studies, leaders can build greater public confidence and streamline complex regulatory pathways.

Furthermore, fostering strategic alliances with local healthcare providers and global research institutions will be instrumental in adapting to diverse market needs. This includes developing region-specific product variants and leveraging localized data to tailor marketing strategies effectively. Taking a proactive approach in identifying and mitigating potential supply chain risks, especially in regions prone to logistical challenges, will ensure consistent vaccine availability and robust distribution networks.

In addition, there should be a concerted focus on workforce training and capacity building. Ensuring that healthcare professionals are well-versed in the latest technologies and vaccination methodologies is key to optimizing immunization results. Finally, a customer-centric strategy that emphasizes clear communication and transparency can facilitate trust among end users, be they clinics, community health centers, or major hospitals. The synthesis of these strategies offers a pathway for industry leaders to not only secure a competitive edge but also contribute meaningfully to global health initiatives.

Conclusion: A Forward-Thinking Perspective for Global Immunization

In conclusion, the combined polio vaccine market is at a strategic crossroads where innovation meets urgent global health needs. The interplay of technological advancements, targeted segmentation, and regional dynamics heralds a promising future for enhanced immunization strategies. With key industry players steering the market through innovation and comprehensive research, the path forward is defined by proactive collaboration and adaptive strategies. This dynamic environment calls for industry leaders to remain vigilant, agile, and committed to continuous improvement as they contribute to the broader mission of disease eradication.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising birth rates and population growth bolster demand for pediatric vaccines across regions
    • 5.1.1.2. Growing emphasis on preventive health care encourages uptake of combination vaccines
    • 5.1.1.3. Government and non-governmental support campaigns enhance vaccine uptake and distribution
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in cold chain logistics and transportation for maintaining vaccine efficacy during distribution
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising investment in cold chain infrastructure improvements for optimal combined polio vaccine efficacy
    • 5.1.3.2. Ongoing research and development for improved vaccine storage and longevity in various climates
  • 5.1.4. Challenges
    • 5.1.4.1. Significant regulatory hurdles for obtaining approval across multiple global markets
• 5.2. Market Segmentation Analysis
  • 5.2.1. Vaccine Type: Increasing need for a bivalent vaccine targeting two poliovirus strains delivering a balance between coverage and cost-effectiveness
  • 5.2.2. Development Stage:
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Combined Polio Vaccine Market, by Vaccine Type

• 6.1. Introduction
• 6.2. Bivalent Vaccine
• 6.3. Monovalent Vaccine
• 6.4. Trivalent Vaccine

7. Combined Polio Vaccine Market, by Route Of Administration

• 7.1. Introduction
• 7.2. Injectable Administration
• 7.3. Oral Administration

8. Combined Polio Vaccine Market, by Technology

• 8.1. Introduction
• 8.2. Inactivated Poliovirus Vaccines
• 8.3. Live Attenuated Vaccines
• 8.4. Subunit Vaccines

9. Combined Polio Vaccine Market, by Development Stage

• 9.1. Introduction
• 9.2. Phase I Clinical Trials
• 9.3. Phase II Clinical Trials
• 9.4. Phase III Clinical Trials
• 9.5. Pre-Clinical Trials

10. Combined Polio Vaccine Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Community Health Centers
• 10.4. Hospitals
• 10.5. Public Health Laboratories

11. Americas Combined Polio Vaccine Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Combined Polio Vaccine Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Combined Polio Vaccine Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. VitriVax secures USD 3.6M grant from Gates Foundation to innovate next-gen polio vaccine formulations
  • 14.3.2. Rice Bioengineers receive USD 3.4m grant to innovate polio vaccine integration
  • 14.3.3. Sanofi secures approval for IMOVAX-polio vaccine in India
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. AstraZeneca PLC
• 3. Bharat Immunologicals and Biologicals Corporation Limited
• 4. Biological E. Limited
• 5. BioNTech SE
• 6. CSL Limited
• 7. Daiichi Sankyo Company, Limited.
• 8. GlaxoSmithKline PLC
• 9. Haffkine Bio-Pharmaceutical Corporation Ltd
• 10. Incepta Pharmaceuticals Ltd.
• 11. Merck & Co., Inc.
• 12. Mitsubishi Tanabe Pharma Corporation
• 13. Panacea Biotec Ltd.
• 14. Pfizer Inc.
• 15. Sanofi S.A.
• 16. Serum Institute of India Pvt. Ltd.
• 17. Sinovac Biotech Ltd.
• 18. Takeda Pharmaceutical Company Limited
• 19. Zydus Lifesciences Limited